Multiple Myeloma Coverage from Every Angle

Prashant Kapoor, MD, and Shaji Kumar, MD, on Bortezomib, Lenalidomide, Dexamethasone With or Without Elotuzumab for Multiple Myeloma

Posted: Wednesday, June 24, 2020

Prashant Kapoor, MD, and Shaji Kumar, MD, both of the Mayo Clinic, discuss phase II results from the SWOG-1211 trial, which support the role of proteasome inhibitor and/or immunomodulatory combination maintenance therapy for patients with newly diagnosed, high-risk multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.